Skip to content

Effect of a scalp cooling device in the prevention of chemotherapy-induced alopecia in breast cancer patients

Effect of a scalp cooling device in the prevention of chemotherapy-induced alopecia in breast cancer patients - Effect of a scalp cooling device in the prevention of chemotherapy-induced alopecia in breast cancer patients

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000027892
Enrollment
30
Registered
2017-06-26
Start date
2017-07-01
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer

Interventions

1.Scalp cooling using the Paxman Scalp Cooling Device was done 30 minutes prior to, during and 90 minutes after each chemo therapy infusion. 2.Patients are instructed to perform gentler hair care tha

Sponsors

Aichi Cancer Center
Lead Sponsor

Eligibility

Sex/Gender
Female

Inclusion criteria

Inclusion criteria: 1.ECOG performance status 0 or 1 2.Adequate bone marrow,heart,liver and renal function 3.Informed consent is obtainable from the subject herself in documented form using the Consent Form

Exclusion criteria

Exclusion criteria: 1.Previous chemotherapy treatment 2.Already have alopecia >grade 1 by CTCAE v4.0 3.History of migraine headaches, hypothyroidism, uncontrolled diabetes, and anorexia. 4.Any condition for contraindication of chemotherapy 5.Multiple active cancers (homochromous multiple cancers, or heterochromous multiple cancers with a cancer-free period of less than 5 years prior to randomization) Carcinoma in situ deemed to be cured by local treatment (lesions that are intraepithelial carcinoma or mucosal cancer) is not included as an active multiple cancer 6.Difficulty to participate in this study due to mental illness or psychiatric symptoms 7.Any other reasons recognized as inadequate to participate in this study by doctors

Design outcomes

Primary

MeasureTime frame
Successful hair preservation assessed using the Common Terminology Criteria for Adverse Events version 4.0 scale (grade0 [no hair loss] or grade 1 [<50% hair loss not requiring a wig]were considered to have hair preservation) at the end of 4 cycles of chemotherapy(TC or weekly PTX) by the physician in charge.

Secondary

MeasureTime frame
1.Wig or head cap use 2.Differences in success rates according to chemotherapy regimen 3.Safety assessment: Adverse events related to device use 4.Safety assessment: Head skin metastasis at 5 years later

Countries

Japan

Contacts

Public ContactHaruru Kotani

Aichi Cancer Center Department of Breast Oncology

k.haruru@aichi-cc.jp052-762-6111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026